Blocking monoclonal antibodies to agr2 and its receptor c4.4a
AssigneeBoard of Regents, The University of Texas System
InventorsCraig D. LOGSDSON, Vijaya RAMACHANDRAN, Thiruvengadam ARUMUGAM
Life of this patent
Estimating the term…
Abstract
Provided herein are monoclonal antibodies that recognize, bind to, and block interactions of other molecules with AGR2 and C4.4A. Also provided herein are methods of using said antibodies to treat cancer.
Claims53
1-81. (canceled)
An isolated monoclonal antibody, wherein the antibody specifically binds to a AGR2 polypeptide and wherein the antibody competes for binding of the polypeptide with a 163-28B-1 monoclonal antibody.
A monoclonal antibody, or an antigen binding fragment thereof, specific to the AGR2 polypeptide wherein the antibody binds specifically to the AGR2 epitope NH2-IHHLDECPHSQALKKVFAENKEIQKLAEQ-C (SEQ ID NO:
- 28).
An isolated monoclonal antibody, wherein the antibody specifically binds to a C4.4A polypeptide and wherein the antibody competes for binding of the polypeptide with a 162-1A-1 monoclonal antibody.
A monoclonal antibody, or an antigen binding fragment thereof, specific to the C4.4A polypeptide wherein the antibody binds specifically to the C4.4A epitope NH2-PVRPTSTTKPMPAPTSQTPRQGVEHEASRDEEPRL-C (SEQ ID NO:
- 29).
A recombinant polypeptide comprising an antibody VH domain comprising CDRs 1-3 of the VH domain of 163-28B-1 (SEQ ID NOs:
- 20, 21, and 22).
A recombinant polypeptide comprising an antibody VH domain comprising CDRs 1-3 of the VH domain of 162-1A-1 (SEQ ID NOs:
- 12, 13, and 14).
A recombinant polypeptide comprising an antibody VL domain comprising CDRs 1-3 of the VL domain of 163-28B-1 (SEQ ID NOs:
- 23, 24, and 25).
A recombinant polypeptide comprising an antibody VL domain comprising CDRs 1-3 of the VL domain of 162-1A-1 (SEQ ID NOs:
- 15, 16, and 17).
A method for treating cancer in a patient comprising administering to the patient an agent that disrupts the AGR2/C4.4A interaction in an amount effective to treat the cancer.
A method for treating a subject having a cancer comprising administering an effective amount of a monoclonal antibody, or antigen binding fragment thereof, which binds specifically to the AGR2 epitope NH2-IHHLDECPHSQALKKVFAENKEIQKLAEQ-C (SEQ ID NO:
- 28).
A method for treating a subject having a cancer comprising administering an effective amount of a monoclonal antibody, or antigen binding fragment thereof, which binds specifically to the C4.4A epitope NH2-PVRPTSTTKPMPAPTSQTPRQGVEHEASRDEEPRL-C (SEQ ID NO:
- 29).
Dependencies are inferred from the claim text.